Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
States a male patient received three doses of SHINGRIX; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 67-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine on 10th September 2020) and Shingrix (received 2nd dose of Shingrix vaccine on 17th November 2020). On 10-FEB-2025, the patient received the 3rd dose of Shingrix. On 10-FEB-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: States a male patient received three doses of SHINGRIX). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 10-FEB-2025 The Healthcare professional was the reporter states that a male patient received three doses of Shingrix, extra dose, which led to extra dose administered. 1st dose was administered on 10-SEP-2020, 2nd dose was administered on 17-NOV-2020 and 3rd dose was received on 10-FEB-2025. No further information was provided including lot number, route or site of administration.